Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

81. Laser prostatectomy for benign prostatic hyperplasia

Laser prostatectomy for benign prostatic hyperplasia Laser prostatectomy for benign prostatic hyperplasia Laser prostatectomy for benign prostatic hyperplasia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Laser prostatectomy for benign prostatic hyperplasia. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Laser prostatectomy (...) is a minimally invasive therapy that uses laser-generated heat to produce coagulation necrosis, to induce vaporization of prostate tissue, or allow for resection of prostate tissue. The laser device is introduced endoscopically through the urethra allowing direct visualization and access to the prostate gland. This procedure is intended as an alternative to traditional surgical transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH). Project page URL Indexing

2006 Health Technology Assessment (HTA) Database.

82. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia

A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia A clinical outcomes and cost analysis comparing (...) photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia Stovsky M D, Griffiths R I, Duff S B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

2006 NHS Economic Evaluation Database.

83. Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms?

Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms? Under what conditions is feedback microwave thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms? Under what conditions is feedback microwave (...) thermotherapy (ProstaLund Feedback Treatment) cost-effective in comparison with alpha-blockade in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms? Ragnarson Tennvall G, Hjelmgren J, Malmberg L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

2006 NHS Economic Evaluation Database.

84. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia

An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia Disantostefano R L, Biddle A K, Lavelle J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined various treatments for benign prostatic hyperplasia (BPH). These included watchful waiting (WW), pharmaceuticals (alpha-blockers, 5-alpha-reductase inhibitors (5-ARIs), combined therapy), transurethral microwave thermotherapy (TUMT) and transurethral resection

2006 NHS Economic Evaluation Database.

85. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Full Text available with Trip Pro

Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The randomised controlled trial suggested that transurethral electrovaporisation of the prostate was as effective in improving the symptoms of benign prostatic enlargement as the current standard transurethral resection and caused less bleeding; but it is unlikely to lead

2005 NIHR HTA programme

86. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2005 Singapore Ministry of Health

87. Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital

Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital Agirbas I, Tatar M, Kisa A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared three surgical treatments for benign prostatic hyperplasia (BPH). The treatments were open prostatectomy, transurethral resection of the prostate (TURP) and laser prostatectomy. Type of intervention Treatment. Economic study type Cost-effectiveness

2005 NHS Economic Evaluation Database.

88. Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis

Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis Bouza C, Lopez T, Magro A, Navalpotro L, Amate J M Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bouza C, Lopez T, Magro A, Navalpotro L, Amate J M. Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). IPE 05/47. 2005 Authors' objectives The aim of this report

2005 Health Technology Assessment (HTA) Database.

89. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia

Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia Fowler C, McAllister W, Plail R, Karim O, Yang Q Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fowler C, McAllister W, Plail R, Karim O, Yang Q. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. Health Technology Assessment 2005; 9(4): 1-44 Authors' objectives The aim of this study was to compare and evaluate the clinical

2005 Health Technology Assessment (HTA) Database.

90. Transurethral electric vaporisation of prostate as an alternate to trans urethral resection in benign prostatic hyperplasia

Transurethral electric vaporisation of prostate as an alternate to trans urethral resection in benign prostatic hyperplasia Transurethral electric vaporisation of prostate as an alternate to trans urethral resection in benign prostatic hyperplasia Transurethral electric vaporisation of prostate as an alternate to trans urethral resection in benign prostatic hyperplasia Akhtar M M, Orakzai N, Qureshi A M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Patients with bladder outflow obstruction symptoms resulting from benign prostatic hyperplasia (BPH) were given transurethral electric vaporisation of the prostate (TUEVP). A 24Fr size resectoscope was used with the cutting mode of diathermy set to 400 watts. The comparator

2004 NHS Economic Evaluation Database.

91. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia McDonald H, Hux M, Brisson M, Bernard L, Nickel J C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined finasteride (FIN), a 5-alpha-reductase inhibitor, either alone or in combination with doxazosin (DOX), an alpha-blocker, for the treatment of benign prostate hyperplasia (BPH). The doses used were 5 mg FIN once daily and 4 mg DOX once daily. Type

2004 NHS Economic Evaluation Database.

92. Benign prostatic hyperplasia. Full Text available with Trip Pro

Benign prostatic hyperplasia. In both ageing men and women, there is an increasing incidence of lower urinary tract symptoms (LUTS) which are increasing. These infections have many possible causes, including smooth muscle dysfunction, neurological factors and benign prostatic hyperplasia. Up to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their quality of life. Although benign prostatic hyperplasia is an important cause of these symptoms, and can have

2003 Lancet

93. Sexual function in patients treated for benign prostatic hyperplasia. (Abstract)

Sexual function in patients treated for benign prostatic hyperplasia. What is the effect of different treatment options for benign prostatic hyperplasia (BPH) on sexual function or dysfunction? With increasing age, sexual dysfunction and BPH become more prevalent. Some treatments for BPH can affect sexual function. Different surgical treatments have different effects on sexual function depending on how much the internal involuntary sphincter is affected. The same is true for medical therapies

2003 Lancet

94. The management of benign prostatic hyperplasia

The management of benign prostatic hyperplasia Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline Clearinghouse

2003 American Urological Association Education and Research, Inc.

95. Holmium laser prostatectomy for benign prostatic hyperplasia: a systematic review

Holmium laser prostatectomy for benign prostatic hyperplasia: a systematic review Holmium laser prostatectomy for benign prostatic hyperplasia: a systematic review Holmium laser prostatectomy for benign prostatic hyperplasia: a systematic review Tooher R L et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tooher R L et al. Holmium (...) laser prostatectomy for benign prostatic hyperplasia: a systematic review. Stepney, SA: Australian Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S) 2003: 147 Authors' objectives The objective of this review was to assess the safety and efficacy of holmium laser prostatectomy, both holmium laser resection of the prostate (HoLRP) and holmium laser enucleation of the prostate (HoLEP), in comparison with transurethral resection of the prostate (TURP) - the current

2003 Health Technology Assessment (HTA) Database.

96. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. Full Text available with Trip Pro

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects (...) therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone.Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need

2003 NEJM Controlled trial quality: uncertain

97. Pygeum africanum for benign prostatic hyperplasia. Full Text available with Trip Pro

Pygeum africanum for benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. The extract of the African prune tree, Pygeum africanum, is one of the several phytotherapeutic agents available for the treatment of BPH.To investigate (...) the evidence whether extracts of Pygeum africanum (1) are more effective than placebo in the treatment of Benign Prostatic Hyperplasia (BPH), (2) are as effective as standard pharmacologic BPH treatments, and (3) have less side effects compared to standard BPH drugs.Trials were searched in computerized general and specialized databases (MEDLINE (1966-2000), EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting relevant manufacturers and researchers.Trials were eligible

2002 Cochrane

98. Economic evaluation of treatment for benign prostatic hyperplasia: transurethral resection vs thermotherapy vs laser vaporization

Economic evaluation of treatment for benign prostatic hyperplasia: transurethral resection vs thermotherapy vs laser vaporization Economic evaluation of treatment for benign prostatic hyperplasia: transurethral resection vs thermotherapy vs laser vaporization Economic evaluation of treatment for benign prostatic hyperplasia: transurethral resection vs thermotherapy vs laser vaporization Aizawa T, Mamiya Y, Namiki K, Okubo Y, Kim T, Arai Y, Ito T, Miki M, Tachibana M Record Status (...) of TURP (lower recurrence) may be more satisfactory in some aspects, but incur very high costs in the event of complications (although none were observed in the present study). Source of funding None stated. Bibliographic details Aizawa T, Mamiya Y, Namiki K, Okubo Y, Kim T, Arai Y, Ito T, Miki M, Tachibana M. Economic evaluation of treatment for benign prostatic hyperplasia: transurethral resection vs thermotherapy vs laser vaporization. Japanese Journal of Urology 2002; 93(7): 736-742 PubMedID

2002 NHS Economic Evaluation Database.

99. TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia

TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Medical Services Advisory Committee. TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia. Canberra: Medical Services Advisory Committee (MSAC) 2002: 93 Authors' objectives TransUrethral Needle Ablation (TUNA) is one of several new minimally invasive thermal technologies for transurethral treatment of the prostate in symptomatic benign prostatic hyperplasia. It is designed to provide selective thermal ablation of the interstitial prostatic tissue. This report

2002 Health Technology Assessment (HTA) Database.

100. Medical management of symptomatic benign prostatic hyperplasia

Medical management of symptomatic benign prostatic hyperplasia Medical management of symptomatic benign prostatic hyperplasia Medical management of symptomatic benign prostatic hyperplasia Malaysian Health Technology Assessment Unit Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Malaysian Health Technology Assessment Unit. Medical management of symptomatic (...) benign prostatic hyperplasia. Kuala Lumpur: Malaysian Health Technology Assessment Unit (MHTAU) 2002 Authors' objectives The objectives of this assessment are to determine the effectiveness, safety and cost implications of the various modalities of medical management of symptomatic benign prostatic hyperplasia (BPH). Authors' conclusions There is sufficient evidence that alpha blockers and 5 alpha reductase inhibitors are effective to treat moderate symptoms of BPH. Alpha blocker are safe

2002 Health Technology Assessment (HTA) Database.